ANIXA BIOSCIENCES, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
ANIXA BIOSCIENCES, INC. (ANIX) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $13.20 million as of 2026-07-31, per its 10-Q filed 2026-09-09.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-09-09
- 2026-07-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $13.20M.
- 2026-04-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $13.22M.
- 2026-01-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $13.85M.
- 2025-10-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $13.95M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed |
|---|---|---|
| 2026-07-31 | $13.20M 10-Q · filed 2026-09-09 | |
| 2026-04-30 | $13.22M 10-Q · filed 2026-09-09 | |
| 2026-01-31 | $13.85M 10-Q · filed 2026-06-10 | |
| 2025-10-31 | $13.95M 10-Q · filed 2026-09-09 | |
| 2025-07-31 | $15.41M 10-Q · filed 2026-09-09 | |
| 2025-04-30 | $14.91M 10-Q · filed 2026-09-09 | |
| 2025-01-31 | $16.71M 10-Q · filed 2026-06-10 | |
| 2024-10-31 | $18.89M 10-Q · filed 2026-09-09 | |
| 2024-07-31 | $20.69M 10-Q · filed 2025-09-10 | |
| 2024-04-30 | $22.58M 10-Q · filed 2025-09-10 | |
| 2024-01-31 | $23.60M 10-Q · filed 2025-05-28 | |
| 2023-10-31 | $23.37M 10-K · filed 2026-01-12 | |
| 2023-07-31 | $24.59M 10-Q · filed 2024-09-06 | |
| 2023-04-30 | $25.91M 10-Q · filed 2024-09-06 | |
| 2023-01-31 | $26.91M 10-Q · filed 2024-06-04 | |
| 2022-10-31 | $28.20M 10-K · filed 2025-01-10 | |
| 2022-07-31 | $30.91M 10-Q · filed 2023-09-06 | |
| 2022-04-30 | $31.41M 10-Q · filed 2023-09-06 | |
| 2022-01-31 | $33.24M 10-Q · filed 2023-06-14 | |
| 2021-10-31 | $34.77M 10-K · filed 2024-01-16 | $34.77M 10-K · filed 2022-01-04 |
| 2021-07-31 | $35.85M 10-Q · filed 2022-09-09 | $35.85M 10-Q · filed 2021-09-01 |
| 2021-04-30 | $37.05M 10-Q · filed 2022-09-09 | $37.05M 10-Q · filed 2021-06-10 |
| 2021-01-31 | $13.08M 10-Q · filed 2022-06-10 | $13.08M 10-Q · filed 2021-03-11 |
| 2020-10-31 | $8.26M 10-K · filed 2023-01-04 | $8.26M 10-K · filed 2021-01-07 |
| 2020-07-31 | $8.14M 10-Q · filed 2021-09-01 | |
| 2020-04-30 | $4.82M 10-Q · filed 2021-09-01 | |
| 2020-01-31 | $5.00M 10-Q · filed 2021-06-10 | |
| 2019-10-31 | $4.81M 10-K · filed 2022-01-04 | |
| 2019-07-31 | $5.40M 10-Q · filed 2020-09-08 | |
| 2019-04-30 | $6.17M 10-Q · filed 2020-09-08 | |
| 2019-01-31 | $5.14M 10-Q · filed 2020-06-09 | |
| 2018-10-31 | $5.18M 10-K · filed 2021-01-07 | |
| 2018-07-31 | $6.16M 10-Q · filed 2019-09-06 | |
| 2018-04-30 | $6.02M 10-Q · filed 2019-09-06 | |
| 2018-01-31 | $6.40M 10-Q · filed 2018-03-09 | |
| 2017-10-31 | $7.92M 10-K · filed 2020-01-09 | |
| 2016-10-31 | $987.48K 10-K · filed 2019-01-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |